NASDAQ
5.71USD
-0.20 (-3.30%)
We have scored 4 news catalysts on Orchestra BioMed Holdings, Inc. (OBIO) over the past 12 months. The biggest single-day move next to one of them came Nov 11, 2025, when OBIO closed +8.5%: “Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates”. Coverage across the window leans mixed (average ticker sentiment +0.03). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
343.5M
P/E
—
EPS
—
Beta
0.52
52W range
3.46-6.5
Day range
5.68–6.02
Open
5.92
Prev close
5.91
Volume
103K
Avg volume
366.1K
Dividend
0.00
IPO
2020-08-04
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Orchestra BioMed Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Orchestra BioMed Holdings, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for OBIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
